CRVS News and Press, Corvus Pharmaceuticals Inc. From 02/10/21

Corvus Pharmaceuticals ([[CRVS]] -8.2%) is set to reverse the double-digit gain recorded yesterday after Mizuho Securities downgraded the stock to neutral from buy citing the company’s recent efforts to reposition the pipeline.The analyst Mara Goldstein and the team note that the compa...

Novel immunotherapy approach designed to stimulate immune response by activating B cells to enhance polyclonal antibody production and potentially reduce hospitalization and progression to respiratory failure Randomized, double-blind, placebo-controlled study expected to enroll ...

We share the remaining top pick ideas from our Marketplace contributors. There are a wide variety - including biotech, precious metals, dividend, and energy ideas. Later on this week we will share the public Google Sheet that will track the performance of these ideas in real-time....

Corvus is a small biotech targeting the adenosine cancer pathway with two assets in clinical development, with a credible path to approval for its A2A Receptor Antagonist. The company is prioritizing development of its CD73 candidate, CPI-006 as a COVID-19 treatment and hopes to initi...

Updated interim d ata from CPI-818 ’s p hase 1/1b c linical t rial provide evidence supporting its potential as a treatment for T cell lymphomas New pre-clinical data provide evidence of CPI-818 poten...

BURLINGAME, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that new data on CPI-818, the Company’s ITK inhibitor, will be presented at the 62 nd American Society of Hematology (ASH...

5 Biotech Stocks To Watch This Week When it comes to biotech stocks , there’s plenty to take into account. This goes for biotech penny stocks as well. Considering that many of these companies are in the preclinical or clinical stages, there’s a higher chance that t...

Data shows CPI-006 provide d enhanced and prolonged polyclonal humoral immunity to SARS - CoV - 2 Plans to initiate pivotal , randomized , double blind trial in December with results expected mid - 2021 ...

Corvus Pharmaceuticals (CRVS) has completed patient enrollment in its Phase 1 study evaluating CPI-006, an immunotherapy approach for hospitalized patients with COVID-19, and updated data from the study will be presented at Society for Immunotherapy of Cancer Annual Meeting.Utilizin...

Data to be presented in a poster and an oral session “ Hot Topic Symposium : COVID-19 and Cancer ” at SITC Data shows CPI-006 provide d enhanced and prolonged polyclonal humoral immunity to SARS - CoV - 2 Plan...